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In recent years, several biomarkers, such as procalcitonin 
(PCT), interleukin-6 (IL-6), soluble triggering receptor 
expressed on myeloid cells-1, and soluble urokinase-type 
plasminogen activator receptor, have been investigated to 
discriminate non-infectious diseases from sepsis. In this 
issue of Critical Care, Que and colleagues [1] describe 
the prognostic value of pancreatic stone protein/re gener-
ating protein (PSP/reg) concentration in patients with 
severe infections.
PSP/reg functions historically have been reported 
mainly in regard to the pancreas, and, indeed, pancreatic 
acinar cells are considered the main source of this 
protein. PSP/reg was initially described as inhibiting 
pancreatic stone formation, but later this role was revised 
[2]. Its serum elevation seemed to be correlated strongly 
with severe acute pancreatitis and less tightly with 
chronic pancreatitis and pancreatic cancer [3]. In the 
’90s, preclinical studies demonstrated that PSP/reg 
appeared to stimulate islet B-cell growth and regeneration 
[4] and recently this function was hypothesized to play a 
role in a therapeutic approach to diabetes mellitus [5]. In 
recent years, PSP/reg investigations bypassed pancreatic 
diseases and focused on infection and inflammation [6]. 
Recent data from Keel and colleagues [7] showed that 83 
patients with severe trauma but not pancreatic trauma 
had PSP/reg upregulation and that the number of 
patients with post-traumatic septic complications 
increased significantly. e authors postulated that PSP/
reg binds and activates neutrophils behaving as an acute-
phase protein that responds to injury during the early 
phase of infection. Boeck and colleagues [8] demon-
strated predictive properties of PSP/reg regarding 
survival in patients with ventilator-associated pneumonia 
with two cutoff values for predicting survival and death 
with high specificity.
e study by Que and colleagues [1] enrolled 107 
patients admitted to the intensive care unit (ICU) with 
severe infections. Within 24 hours after ICU admission, 
the authors measured the concentrations of PSP/reg, C-
reactive protein, PCT, inflammatory cytokines, leukocyte 
count, and severity scores  – Acute Physiology and 
Chronic Health Evaluation II (APACHE II), Simplified 
Acute Physiology Score (SAPS) II and III, and Sequential 
Organ Failure Assessment (SOFA) – and correlated all of 
these parameters with in-hospital mortality. e authors 
demonstrated that PSP/reg and SAPS III were the only 
two variables associated with mortality and thus con-
cluded that PSP/reg is the only bedside biomarker useful 
in predicting the outcome of patients with sepsis. e 
data presented in the article are sound, but several 
questions arise: Is PSP/reg related to infection or to tissue 
hypoperfusion? Do comorbidities affect PSP/reg values 
in patients with sepsis? Is a single PSP/reg measurement 
helpful in clinical practice?
Tumor necrosis factor-alpha, interferon-gamma, and 
IL-6 are known to induce PSP/reg expression and thus 
PSP/reg can be assumed as a potential sepsis marker [9]. 
Nevertheless, to our knowledge, no studies on PSP/reg 
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Rapid diagnosis, appropriate management, and time 
are the key factors for improving survival rate in many 
emergency clinical scenarios such as acute myocardial 
infarction, pulmonary embolism, cerebral stroke, and 
severe sepsis. Clinical signs and electrocardiographic, 
radiological, and echographic investigations associated 
with biomarkers usually allow a quick diagnosis in all of 
the above situations, except severe sepsis, in which the 
diagnosis in the early phases is often only presumptive. 
In sepsis, microbiological cultures are still considered 
the ‘gold standard’ for diagnosis, whereas the numerous 
biomarkers investigated are actually valuable only 
for patient stratication and evaluation of clinical 
course. In this issue of Critical Care, Que and colleagues 
describe the prognostic value of pancreatic stone 
protein/regenerating protein (PSP/reg) concentration 
in patients with severe infections. The data reported are 
interesting, but several questions about this biomarker 
arise, and further studies are needed to understand its 
role in sepsis and clinical practice.
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concentrations in other types of shock (that is, hemor-
rhagic or cardiogenic) have been performed. So the high 
values observed in patients with septic shock may not 
necessarily be related to the infection pathway but may 
be due to tissue hypoperfusion or systemic inflam matory 
response or both. PSP/reg is increased in patients with 
chronic renal failure, gastric cancer, peptic ulcer, liver 
cirrhosis, or diabetes mellitus [2]. Que and colleagues [1] 
reported that ‘most patients had at least one comorbid 
condition’, but unfortunately the authors did not analyze 
how these comorbidities affected the initial levels of PSP/
reg. A useful biomarker ought to fulfill different clinical 
needs such as early diagnosis and accurate evaluation of 
clinical course. A single PSP/reg measurement correlated 
with the severity of the disease, but we do not know 
whether this biomarker is reliable in the early diagnosis 
of bacterial infection or, for instance, in monitoring the 
therapy response. Que and colleagues added new and 
interesting findings on the relationships between PSP/reg 
and patients with severe sepsis. However, there is a long 
way to go before PSP/reg, along with other biomarkers, 
can be implemented in clinical practice.
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